Login / Signup

A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.

Gyungah KimEun-Ji ChoiHan-Seung ParkJung Hee LeeJe Hwan LeeKyoo Hyung Lee
Published in: Journal of Korean medical science (2021)
Immune thrombocytopenia (ITP) is an autoimmune condition characterized by platelet destruction through antibody-mediated mechanism. ITP is one of the manifestations of a coronavirus disease, as well as an adverse event occurring after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several cases of ITP have been described after vaccination with two mRNA-based vaccines-BTN162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)-against SARS-CoV-2. Herein, we report a case of ITP occurring after vaccination with ChAdOx1 adenovirus vector nCoV-19 (AstraZeneca) vaccine in Korea. A 66-year-old woman presented with multiple ecchymoses on both upper and lower extremities and gingival bleeding, appearing 3 days after receiving the first dose of ChAdOx1 nCoV-19. Her laboratory results showed isolated severe thrombocytopenia without evidence of combined coagulopathy. She was diagnosed with ITP and successfully treated with high-dose dexamethasone and intravenous immunoglobulin. Clinical suspicion to identify vaccine-related ITP is important to promptly initiate appropriate treatment.
Keyphrases
  • respiratory syndrome coronavirus
  • sars cov
  • high dose
  • coronavirus disease
  • low dose
  • stem cell transplantation
  • multiple sclerosis
  • emergency department
  • drug induced
  • early onset
  • soft tissue